Optimal wavelength for the clot waveform analysis: Determination of the best resolution with minimal interference of the reagents.


Journal

International journal of laboratory hematology
ISSN: 1751-553X
Titre abrégé: Int J Lab Hematol
Pays: England
ID NLM: 101300213

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 12 10 2018
revised: 19 12 2018
accepted: 04 01 2019
pubmed: 8 2 2019
medline: 13 11 2019
entrez: 8 2 2019
Statut: ppublish

Résumé

Clot waveform analysis (CWA), a new methodology to assess coagulation process, can be usefully applied in various clinical settings. However, its clinical use is limited mainly because of the absence of standardization. No consensus exists regarding the wavelengths at which CWA has to be performed what is crucial for the sensitivity of the CWA. The primary aim of this study is to determine which wavelength is the most sensitive and specific for CWA. Interindividual baseline absorbance will also be assessed as the impact of reagents from the intrinsic, extrinsic, and common coagulation pathway will be determined. Plasma samples were screened at wavelengths from 280 to 700 nm to provide absorbance spectra in clotted and nonclotted plasma. The interindividual variability of baseline absorbance was obtained by screening plasma from 50 healthy individuals at 340, 635, and 671 nm. The inner-filter effect of reagents was assessed in plasma or serum when appropriate at the same wavelengths. The reagents were those commonly used for activated partial thromboplastin time, prothrombin time, thrombin time, and dilute Russell's viper venom time. Clotted plasma has higher absorbance value than nonclotted plasma (P < 0.01). The absorbance of all type of samples is higher at 340 nm than at >600 nm (P < 0.01). The interindividual variability at the different wavelengths was around 25%. However, except with the STA®-CKPrest® and STA®-NeoPTimal®, the reagents do not have a significant effect on the baseline absorbance. Wavelengths above 650 nm are recommended to perform CWA. Most of the commercialized reagents can be used for CWA.

Identifiants

pubmed: 30730600
doi: 10.1111/ijlh.12975
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

316-324

Informations de copyright

© 2019 John Wiley & Sons Ltd.

Auteurs

Jonathan Evrard (J)

Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium.

Romain Siriez (R)

Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium.

Laure Morimont (L)

Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium.

Pauline Thémans (P)

Department of Mathematics, Namur Institute for Complex System (naXys), University of Namur, Namur, Belgium.

Julie Laloy (J)

Department of Pharmacy, Namur Nanosafety Center (NNC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium.

Céline Bouvy (C)

Qualiblood s.a., Namur, Belgium.

Damien Gheldof (D)

Qualiblood s.a., Namur, Belgium.

François Mullier (F)

CHU UCL Namur, Hematology Laboratory, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Université Catholique de Louvain, Yvoir, Belgium.

Jean-Michel Dogné (JM)

Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium.

Jonathan Douxfils (J)

Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium.
Qualiblood s.a., Namur, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH